Ocera Therapeutics clinical trials
Acquired by Keenova Therapeutics plc, Dec 11, 2017 · source ↗
The registry lists 10 studies whose lead sponsor is Ocera Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 20, 2021.
Before and after it joined Keenova Therapeutics plc
- First submitted before Ocera Therapeutics became part of Keenova Therapeutics plc
- 10
- First submitted after Ocera Therapeutics became part of Keenova Therapeutics plc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Ocera Therapeutics7 studies
- Ocera Therapeutics, Inc.3 studies
Something wrong with this grouping? Tell us on the Keenova Therapeutics plc page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Keenova Therapeutics plc studies →
- OCR002-SP103 - Oral Immediate Release StudyCompletedNCT03846843Phase 1
Sponsor listed in the registry: Ocera Therapeutics, Inc. · First submitted before Ocera Therapeutics, Inc. became part of Keenova Therapeutics plc
- Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)CompletedNCT01966419Phase 2
Sponsor listed in the registry: Ocera Therapeutics, Inc. · First submitted before Ocera Therapeutics, Inc. became part of Keenova Therapeutics plc
- Emergency Use of OCR-002 in Acute Liver Failure (ALF)No longer availableNCT01634230
Sponsor listed in the registry: Ocera Therapeutics, Inc. · First submitted before Ocera Therapeutics, Inc. became part of Keenova Therapeutics plc
- Safety and Efficacy of AST-120 in the Treatment of PouchitisCompletedNCT00583076Phase 2
Sponsor listed in the registry: Ocera Therapeutics · First submitted before Ocera Therapeutics became part of Keenova Therapeutics plc
- Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory PouchitisTerminatedNCT00583531Phase 2
Sponsor listed in the registry: Ocera Therapeutics · First submitted before Ocera Therapeutics became part of Keenova Therapeutics plc
- Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPITerminatedNCT00587275Phase 2
Sponsor listed in the registry: Ocera Therapeutics · First submitted before Ocera Therapeutics became part of Keenova Therapeutics plc
- Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel SyndromeCompletedNCT00583128Phase 2
Sponsor listed in the registry: Ocera Therapeutics · First submitted before Ocera Therapeutics became part of Keenova Therapeutics plc
- AST-120 Used to Treat Mild Hepatic EncephalopathyCompletedNCT00867698Phase 2
Sponsor listed in the registry: Ocera Therapeutics · First submitted before Ocera Therapeutics became part of Keenova Therapeutics plc
- Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With FistulasCompletedNCT00321412Phase 3
Sponsor listed in the registry: Ocera Therapeutics · First submitted before Ocera Therapeutics became part of Keenova Therapeutics plc
- Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic EncephalopathyCompletedNCT00558038Phase 2
Sponsor listed in the registry: Ocera Therapeutics · First submitted before Ocera Therapeutics became part of Keenova Therapeutics plc